More mixed Entereg data
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GSK and Adolor announce initial top-line results from two Phase II studies of the peripheral mu opioid receptor antagonist Entereg (alvimopan) March 7, one positive and one failed. Entereg was statistically significant for all doses for all endpoints in a Phase IIb study (011) in 522 non-cancer patients with opioid-induced bowel dysfunction. A Phase IIa proof-of-concept study (007) in chronic idiopathic constipation not due to opioid treatment, however, failed to show significant difference from placebo for any dose on any endpoint. "Exploratory analyses of these data...suggest that some constipated patients may have achieved therapeutic benefits and so further studies are being considered," the firms said. GSK/Adolor's Entereg NDA for treatment of post-operative ileus is based on mixed trial results. Entereg has an April 25 action date, but the firms are expecting a 90-day extension following submission of FDA-requested data (1Pharmaceutical Approvals Monthly January 2005, p. 36)...
You may also be interested in...
FDA Requests Entereg Failed European Study Data, Adolor Says
FDA requests Entereg failed European study data, Adolor reports. Alvimopan failed to show statistical significance for the primary endpoint in partner GlaxoSmithKline’s Phase III study. The pending NDA for the postoperative ileus therapy is based on three studies with mixed results
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.